Background Antibodies to the cysteine-rich domain II of Plasmodium vivax Duffy binding
protein (PvDBP) can inhibit binding of this parasite ligand to its receptor on red blood cells …

We present evidence for Plasmodium vivax infection among Duffy blood group-negative
inhabitants of Brazil. The P. vivax identification was determined by both genotypic and non …

Background and Objectives Duffy blood group is of major interest in clinical medicine as it is
not only involved in blood‐transfusion risks and occasionally in neonatal haemolytic …

Plasmodium vivax remains an important cause of morbidity outside Africa, and no effective
vaccine is available against this parasite. The P. vivax Duffy binding protein (PvDBP) is …

We present evidence that a parasite with characteristics of Plasmodium vivax is being
transmitted among Duffy blood group–negative inhabitants of Kenya. Thirty-two of 4,901 …

Region II of Duffy binding protein (PvDBP-II) is one of the most promising blood-stage
vaccine candidate antigens against Plasmodium vivax and having knowledge of the nature …

Vivax malaria has long been thought to be absent from sub-Saharan Africa owing to the high
proportion of individuals lacking the Duffy antigen receptor for chemokines (DARC) in their …

Plasmodium vivax Duffy binding protein (PvDBP) is a micronemal type I membrane protein
that plays an essential role in erythrocyte invasion of merozoites. PvDBP is a prime blood …

Plasmodium vivax is the leading cause of human malaria in Asia and Latin America but is
absent from most of central Africa due to the near fixation of a mutation that inhibits the …

Plasmodium vivax Duffy binding protein (DBP) is vital for parasite development, thereby
making this molecule a good vaccine candidate. Preclinical development of a P. vivax …